Breast Cancer

Breast cancer is one of the major health problems facing the world today, being a significant contributor to overall morbidity and mortality. In order to make the greatest impact on breast cancer patients the following aspects need to be taken into account: 1) the identification of women predisposed to breast cancer by risk prediction markers and/or risk factors and 2) the application of a preventive or early detection strategy. This need is further magnified by the current controversies of the efficacy of breast cancer screening and the concern about over diagnosis and unnecessary treatment. In the last decades, a huge effort has been made to identify risk factors and biomarkers associated with breast cancer that can be used for risk stratification. Our group has a major interest in identifying novel biomarkers and factors that could be used for risk stratification and on that basis we have set up several internal studies and external collaborations.

Discovery and validation of early biomarkers of breast cancer

  • John Timms (UCL), Usha Menon, Aleksandra Gentry-Maharaj (UCL)
  • Eve Appeal 

EPI-FEM-CARE Breast Cancer epigenetics

  • Martin Widschwendter (UCL), Shazia Anjum, Alison Jones, A Wong (UCL); David Cibula (Charles University Hospital, Prague, Czech Republic), Ian Jacobs, Usha Menon,  (UCL)
  • EU FP7 Grant

RANKL, OPG, Prolactin and CCL5 in breast cancer

  • Martin Widschwendter (UCL); Joseph Penninger (Institute of Molecular Biotechnology GmbH, Vienna, Austria), Ian Jacobs, Usha Menon (UCL)
  • Eve Appeal 

Risk factors in breast cancer 

  • Martin Widschwendter (UCL), Shazia Anjum, Alison Jones, A Wong (UCL); David Cibula (Charles University Hospital, Prague, Czech Republic), Ian Jacobs, Usha Menon,  (UCL)
  • CBRC, UCLH/UCL

Risk factors in breast cancer (Rania Fourkala PhD thesis)

  • Martin Widschwendter (UCL), Usha Menon,  (UCL)
  • MRC